Relay Therapeutics Q1 2026 net loss $73.3M; FDA BTD for zovegalisib; cash $642M

Relay Therapeutics, Inc.

2026-Q1 EPS reported -$0.41 revenue$3,000,000

FDA granted Breakthrough Therapy designation to zovegalisib+fulvestrant for PIK3CA-mutant HR+/HER2- advanced breast cancer.
Median PFS 11.1 months in heavily pre-treated patients; similar efficacy across kinase and non-kinase mutations.
Phase 3 1L trial of zovegalisib+atirmociclib expected early 2027; Pfizer to supply atirmociclib.
Initiated Phase 1/2 trial of RLY-8161, an NRAS-selective inhibitor, in NRAS-mutant solid tumors.
Cash, cash equivalents and investments $642.1M; net loss $73.3M ($0.41 per share) for Q1 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.